(Q38139837)

29 August 2017

title

New avenues for anti-epileptic drug discovery and development (English)

1 reference

29 August 2017

1 reference

Wolfgang Löscher

1

1 reference

29 August 2017

Henrik Klitgaard

series ordinal

2

1 reference

29 August 2017

Roy E Twyman

series ordinal

3

1 reference

29 August 2017

Dieter Schmidt

series ordinal

4

1 reference

29 August 2017

publication date

20 September 2013

1 reference

Nature Reviews Drug Discovery

29 August 2017

published in

1 reference

29 August 2017

volume

12

1 reference

29 August 2017

issue

10

1 reference

29 August 2017

page(s)

757-776

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd4126

29 August 2017

exact match

0 references

cites work

Evidence-based review on the natural history of the epilepsies.

1 reference

Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009

31 March 2020

1 reference

Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma

31 March 2020

1 reference

Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study

31 March 2020

1 reference

Patterns of treatment response in newly diagnosed epilepsy.

31 March 2020

1 reference

Early treatment suppresses the development of spike-wave epilepsy in a rat model

31 March 2020

1 reference

Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy

31 March 2020

1 reference

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial

31 March 2020

1 reference

The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial

31 March 2020

1 reference

KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy

31 March 2020

1 reference

Enzyme induction with antiepileptic drugs: cause for concern?

31 March 2020

1 reference

Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis

31 March 2020

1 reference

Key factors in the discovery and development of new antiepileptic drugs

31 March 2020

1 reference

Development of new antiepileptic drugs: challenges, incentives, and recent advances

31 March 2020

1 reference

EXPERIMENTAL DETERMINATION OF THE ANTICONVULSANT PROPERTIES OF SOME PHENYL DERIVATIVES

31 March 2020

1 reference

Properties of maximal seizures, and their alteration by anticonvulant drugs and other agents

31 March 2020

1 reference

Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs

31 March 2020

1 reference

Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy

31 March 2020

1 reference

Multiple facets of GABAergic neurons and synapses: multiple fates of GABA signalling in epilepsies

31 March 2020

1 reference

Clinical trials for therapeutic assessment of antiepileptic drugs in the 21st century: obstacles and solutions

31 March 2020

1 reference

Antiepileptic Drug Development: I. History and a Program for Progress

31 March 2020

1 reference

Antiepileptic drug development: II. Anticonvulsant drug screening

31 March 2020

1 reference

Levetiracetam: the first SV2A ligand for the treatment of epilepsy

31 March 2020

1 reference

Carbamazepine, but not valproate, displays pharmacoresistance in lamotrigine-resistant amygdala kindled rats

31 March 2020

1 reference

A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group

31 March 2020

1 reference

Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy

31 March 2020

1 reference

Is the underlying cause of epilepsy a major prognostic factor for recurrence?

31 March 2020

1 reference

A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of adjunctive carisbamate treatment in patients with partial-onset seizures

31 March 2020

1 reference

A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures

31 March 2020

1 reference

Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials

31 March 2020

1 reference

Clinical features associated with placebo response in refractory focal epilepsy.

31 March 2020

1 reference

The placebo response in medicine: minimize, maximize or personalize?

31 March 2020

1 reference

Early seizure frequency and aetiology predict long-term medical outcome in childhood-onset epilepsy

31 March 2020

1 reference

Quantifying the response to antiepileptic drugs: effect of past treatment history

31 March 2020

1 reference

Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society

31 March 2020

1 reference

Stiripentol : in severe myoclonic epilepsy of infancy (dravet syndrome).

31 March 2020

1 reference

Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes

31 March 2020

1 reference

Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research

31 March 2020

1 reference

Mechanisms of epileptogenesis and potential treatment targets

31 March 2020

1 reference

Antiepileptic and antiepileptogenic performance of carisbamate after head injury in the rat: blind and randomized studies.

31 March 2020

1 reference

mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy

31 March 2020

1 reference

Defining "epileptogenesis" and identifying "antiepileptogenic targets" in animal models of acquired temporal lobe epilepsy is not as simple as it might seem

31 March 2020

1 reference

The neurobiology of antiepileptic drugs

31 March 2020

1 reference

Epilepsy: perampanel-new promise for refractory epilepsy?

31 March 2020

1 reference

Antiepileptic drug therapy: does mechanism of action matter?

31 March 2020

1 reference

The pharmacology of new antiepileptic drugs: does a novel mechanism of action really matter?

31 March 2020

1 reference

Antiepileptic drug discovery: does mechanism of action matter?

31 March 2020

1 reference

Identifying targets for preventing epilepsy using systems biology

31 March 2020

1 reference

Dysregulation of the TSC-mTOR pathway in human disease

31 March 2020

1 reference

Before epilepsy unfolds: finding the epileptogenesis switch

31 March 2020

1 reference

Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy

31 March 2020

1 reference

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

31 March 2020

1 reference

On the origin of interictal activity in human temporal lobe epilepsy in vitro.

31 March 2020

1 reference

Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments

31 March 2020

1 reference

NKCC1 transporter facilitates seizures in the developing brain

31 March 2020

1 reference

GABAergic excitation after febrile seizures induces ectopic granule cells and adult epilepsy.

31 March 2020

1 reference

Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy

31 March 2020

1 reference

Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy

31 March 2020

1 reference

The role of cytokines in the pathophysiology of epilepsy

31 March 2020

1 reference

The role of inflammation in epilepsy

31 March 2020

1 reference

The role of inflammation in epileptogenesis

31 March 2020

1 reference

New roles for interleukin-1 Beta in the mechanisms of epilepsy

31 March 2020

1 reference

Focal seizures due to chronic localized encephalitis

31 March 2020

1 reference

IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures

31 March 2020

1 reference

Interleukin-1β biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice

31 March 2020

1 reference

Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI)

31 March 2020

1 reference

Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice

31 March 2020

1 reference

Functional role of inflammatory cytokines and antiinflammatory molecules in seizures and epileptogenesis

31 March 2020

1 reference

Seizure-induced brain-borne inflammation sustains seizure recurrence and blood-brain barrier damage.

31 March 2020

1 reference

Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures

31 March 2020

1 reference

A role for leukocyte-endothelial adhesion mechanisms in epilepsy

31 March 2020

1 reference

Leukocyte trafficking mechanisms in epilepsy

31 March 2020

1 reference

Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report

31 March 2020

1 reference

Blood-brain barrier breakdown-inducing astrocytic transformation: novel targets for the prevention of epilepsy

31 March 2020

1 reference

Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury

31 March 2020

1 reference

Blood-brain barrier dysfunction, TGFβ signaling, and astrocyte dysfunction in epilepsy

31 March 2020

1 reference

Long-lasting pro-ictogenic effects induced in vivo by rat brain exposure to serum albumin in the absence of concomitant pathology.

31 March 2020

1 reference

Transcriptome profiling reveals TGF-beta signaling involvement in epileptogenesis

31 March 2020

1 reference

Finding a better drug for epilepsy: antiepileptogenesis targets.

31 March 2020

1 reference

Epigenetics and epilepsy.

31 March 2020

1 reference

Neuron-restrictive silencer factor-mediated hyperpolarization-activated cyclic nucleotide gated channelopathy in experimental temporal lobe epilepsy

31 March 2020

1 reference

Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects

31 March 2020

1 reference

The emerging role of DNA methylation in epileptogenesis

31 March 2020

1 reference

Nrf2 defense pathway: Experimental evidence for its protective role in epilepsy.

31 March 2020

1 reference

A systems level, functional genomics analysis of chronic epilepsy

31 March 2020

1 reference

Neuronal sensitivity to kainic acid is dependent on the Nrf2-mediated actions of the antioxidant response element

31 March 2020

1 reference

Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway

31 March 2020

1 reference

An integrative genomics approach to infer causal associations between gene expression and disease

31 March 2020

1 reference

Epileptogenesis-related genes revisited.

31 March 2020

1 reference

Functional anatomy of limbic epilepsy: a proposal for central synchronization of a diffusely hyperexcitable network

31 March 2020

1 reference

Connectomics and epilepsy

31 March 2020

1 reference

Pharmacoresistance and the role of surgery in difficult to treat epilepsy

31 March 2020

1 reference

Network pharmacology: the next paradigm in drug discovery

31 March 2020

1 reference

31 March 2020

Networking for new drugs

1 reference

Systems biology impact on antiepileptic drug discovery

31 March 2020

1 reference

Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy

31 March 2020

1 reference

Neuroprotective and antiepileptogenic effects of combination of anti-inflammatory drugs in the immature brain.

31 March 2020

1 reference

Drug resistance in brain diseases and the role of drug efflux transporters.

31 March 2020

1 reference

Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy

31 March 2020

1 reference

P-glycoprotein imaging in temporal lobe epilepsy: in vivo PET experiments with the Pgp substrate [11C]-verapamil

31 March 2020

1 reference

P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study.

31 March 2020

1 reference

Increased risk of death among children with Lennox-Gastaut syndrome and infantile spasms.

31 March 2020

1 reference

Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalin

31 March 2020

1 reference

Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms

31 March 2020

1 reference

Molecular and cellular mechanisms of pharmacoresistance in epilepsy

31 March 2020

1 reference

New developments in antiepileptic drug resistance: an integrative view

31 March 2020

1 reference

Role of CNS efflux drug transporters in antiepileptic drug delivery: overcoming CNS efflux drug transport

31 March 2020

1 reference

The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy

31 March 2020

1 reference

Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected

31 March 2020

1 reference

The transport of antiepileptic drugs by P-glycoprotein

31 March 2020

1 reference

The clinical impact of pharmacogenetics on the treatment of epilepsy

31 March 2020

1 reference

Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam

31 March 2020

1 reference

Basic mechanisms of antiepileptic drugs and their pharmacokinetic/pharmacodynamic interactions: an update

31 March 2020

1 reference

Pharmacodynamic interactions between antiepileptic drugs: preclinical data based on isobolography

31 March 2020

1 reference

Combining antiepileptic drugs--rational polytherapy?

31 March 2020

1 reference

Adverse effects of antiepileptic drugs

31 March 2020

1 reference

Drug treatment of epilepsy: options and limitations

31 March 2020

1 reference

Do preclinical seizure models preselect certain adverse effects of antiepileptic drugs

31 March 2020

1 reference

Responses to NMDA receptor antagonists altered by epileptogenesis

31 March 2020

1 reference

Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation?

31 March 2020

1 reference

Use of epileptic animals for adverse effect testing

31 March 2020

1 reference

Lamotrigine (Lamictal IR) for the treatment of bipolar disorder

31 March 2020

1 reference

Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology

31 March 2020

1 reference

The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions.

31 March 2020

1 reference

Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X).

31 March 2020

1 reference

Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders?

31 March 2020

1 reference

Dopamine abnormalities in the neocortex of patients with temporal lobe epilepsy.

31 March 2020

1 reference

Common factors among Alzheimer's disease, Parkinson's disease, and epilepsy: possible role of the noradrenergic nervous system

31 March 2020

1 reference

Biomarkers in epilepsy: introduction

31 March 2020

1 reference

Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design.

31 March 2020

1 reference

High-frequency oscillations: what is normal and what is not?

31 March 2020

1 reference

Leveraging biomarker platforms and systems biology for rehabilomics and biologics effectiveness research

31 March 2020

1 reference

Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot

31 March 2020

1 reference

The state of innovation in drug development

31 March 2020

1 reference

Lessons from 60 years of pharmaceutical innovation

31 March 2020

1 reference

How to improve R&D productivity: the pharmaceutical industry's grand challenge

31 March 2020

1 reference

Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies

31 March 2020

1 reference

Striking differences in individual anticonvulsant response to phenobarbital in rats with spontaneous seizures after status epilepticus.

31 March 2020

1 reference

Hazards of inference: the active control investigation

31 March 2020

1 reference

Clinical trials for prevention of epileptogenesis.

31 March 2020

1 reference

Progress on the issue of excitotoxic injury modification vs. real neuroprotection; implications for post-traumatic epilepsy

31 March 2020

1 reference

Human clinical trails in antiepileptogenesis

31 March 2020

1 reference

A permanent change in brain function resulting from daily electrical stimulation

31 March 2020

1 reference

Evidence suggesting secondary epileptogenic lesions after kainic acid: pretreatment with diazepam reduces distant but not local brain damage

31 March 2020

1 reference

Spontaneous paroxysmal electroclinical patterns in rat: a model of generalized non-convulsive epilepsy.

31 March 2020

1 reference

Long-term effects of pilocarpine in rats: structural damage of the brain triggers kindling and spontaneous recurrent seizures.

31 March 2020

1 reference

Is antiepileptogenesis a realistic goal in clinical trials? Concerns and new horizons.

31 March 2020

1 reference

12 December 2020

Antiepileptic drugs: advantages and disadvantages

1 reference

12 December 2020

Psychiatric comorbidity in epilepsy: a population-based analysis.

1 reference

12 December 2020

Treatment of pediatric epilepsy: European expert opinion, 2007.

1 reference

12 December 2020

Preventing and treating posttraumatic seizures: the human experience

1 reference

12 December 2020

Kindling as a model of drug-resistant partial epilepsy: selection of phenytoin-resistant and nonresistant rats

1 reference

12 December 2020

The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs

1 reference

12 December 2020

Comparative assays of antiepileptic drugs in mice and rats

1 reference

12 December 2020

What clinical trial designs have been used to test antiepileptic drugs and do we need to change them?

1 reference

12 December 2020

Basic mechanisms of seizure propagation: targets for rational drug design and rational polypharmacy.

1 reference

12 December 2020

Laboratory assay of clinically effective antiepileptic drugs

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD4126

1 reference

Dimensions Publication ID

29 August 2017

1019475641

0 references

Fatcat ID

release_yunehw7svfbpzifsfjx3tcqnqe

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yunehw7svfbpzifsfjx3tcqnqe

24 November 2022

mapped directly with Wikidata item

1 reference